Lilly Drug Slows Alzheimer’s Mental Decline in Second Analysis

Lilly Drug Slows Alzheimer’s Mental Decline in Second Analysis

Victor J. Blue/Bloomberg

To market the drug solanezumab, Eli Lilly & Co. may need to do another study to confirm the findings, said Maria Carrillo, a vice president of medical and scientific relations at the Alzheimer’s Association.